“…Studies of concomitant use are typically conducted when 2 vaccines are likely to be administered at the same time for programmatic efficiency. With only a few exceptions, seroconversion rates and adverse event frequency are not impacted by simultaneous administration of the most-commonly used live and inactivated vaccines [ 48 – 50 ]. One study has convincingly demonstrated that concomitant administration of Hecolin with another protein-based vaccine, hepatitis B, was both safe and did not adversely affect immune response to either vaccine [ 51 ].…”